
Manufacturing roundup: Astellas to sell Dutch facility to Delpharm; Aurigene investing $40M into India manufacturing facility
Astellas Pharma is selling its manufacturing plant in Meppel, the Netherlands, to contract manufacturer Delpharm.
Astellas said last week it’s transferring the facility to Delpharm as part of a wider shift for the pharma’s technology and manufacturing business. As part of the deal, for which financial details were not disclosed, Delpharm plans to continue to produce the products that are made in the Meppel plant for Astellas. The employees at the site will also transfer to Delpharm as well. The deal is expected to close by the end of the year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.